PanOptica snags $45 mln Series B funds

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

SAGE Therapeutics secures $20m Series B financing

Biopharmaceutical company SAGE Therapeutics has secured a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011. The Series B financing will accelerate clinical and preclinical efforts to continue to advance SAGE’s pipeline programs in CNS disorders.

Taris Biomedical Raises $12.5 Million

Taris Biomedical, a specialty pharmaceutical company developing therapies to treat bladder diseases, has raised a fresh $12.5 million in funding from its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures. With the new funding, Taris, based in Lexington, Mass., has raised $49.8 million altogether.

Cibiem Appoints President and CEO

Medical device company Cibiem has appointed Ken Martin to president and chief executive officer. Martin will succeed Cibiem co-founder Howard R. Levin who will continue his active involvement within the company and as a member of its board of directors.The company is backed by SV Life Sciences and Third Rock Ventures.

Kala Pharmaceuticals Secures $11.5m Series A

Kala Pharmaceuticals has secured $11.5 million in Series A equity financing through new and existing investors. New and lead investor Crown Venture Fund the venture capital arm of the Crown family of Chicago, joined Kala’s existing investors including Lux Capital Management, Polaris Venture Partners and Third Rock Ventures.

Shire Acquires Lotus Tissue Repair

Shire has signed an agreement to acquire Lotus Tissue Repair. The business is a private biotechnology company launched in 2011 by a team of biotechnology entrepreneurs and life sciences investor, Third Rock Ventures.

Blueprint Medicines Makes Chris Varma Permanent CEO; Names Daniel Lynch Executive Chairman

Blueprint Medicines, a Cambridge, Mass.-based company that’s developing cancer therapies, has made Chris Varma, its founding president and an entrepreneur-in-residence at Third Rock Ventures, its permanent president and CEO. The company has also named Daniel Lynch as executive chairman of its board. Lynch spent nearly five years at ImClone Systems, including as CEO and CFO.

Igenica Closes $33 Million in Series C Funding

California-based antibody biopharma company Igenica has raised $33 million in a Series C round led by new investor Third Rock Ventures. Existing backers The Column Group, Orbimed Advisors and 5AM Ventures participated in the round; Igenica has raised about $55 million to date. PRESS RELEASE: BURLINGAME, Calif., June 12, 2012 /PRNewswire/ — Igenica, Inc., a […]

Alcresta Raises $10M Series A

Alcresta, a Newton, Mass.-based company that is developing enzyme-based nutritional products, has raised $10 million in Series A financing led by Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. PRESS RELEASE: Alcresta, a company developing innovative enzyme-based nutritional products for infants, adults and patients battling acute or chronic conditions, today announced a $10 million Series […]

Sanofi Invests $125 Million in Warp Drive Bio

Boston-based Third Rock Ventures today launched the genomic search engine start-up, Warp Drive Bio, as part of a partnership with the French pharmaceutical company Sanofi. Sanofi is investing $125 million into the company, which Third Rock — an venture firm as well as incubator — has been developing for the last two years. PRESS RELEASE: […]

VC-backed Seventh Sense Inks $3.28M Grant

Seventh Sense Biosystems Inc., a Cambridge, Mass.-based developer of technology for decentralized diagnostic testing, has sealed a $3.28 million grant from the Bill & Melinda Gates Foundation. Formed in 2008, the company is backed by investors including Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.

Third Rock Ventures Launches Ember Therapeutics with $34M

Boston-based Third Rock Ventures has unveiled a new company, Ember Therapeutics, a product-focused company that’s trying to harness breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Third Rock, a venture firm that helps incubate life sciences companies, has given Ember $34 million in Series A financing. PRESS RELEASE: BOSTON, Dec […]

Agios Pharmaceuticals Seals $78M Series C

Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Allena Pharmaceuticals Launches with $15M

Allena Pharmaceuticals Inc., a company developing oral protein therapeutics, has raised $15 million in a first round of venture funding. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the Series A round. The funding will help fund development. Allena Pharmaceuticals is based in Newton, Mass.

Third Rock Ventures Launches SAGE Therapeutics

Third Rock Ventures has launched SAGE Therapeutics with a $35 million Series A financing. SAGE’s efforts focus on advancing a pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia, depression, pain and traumatic brain injury (TBI).

TOPICA Pharmaceuticals Closes $27M Series B

Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corp. have poured $27 million into privately held biotechnology company TOPICA Pharmaceuticals. The Series B round will be used for continued development of the company’s broad-spectrum topical antifungal agent, the company said Tuesday.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget